

# Thomas J George

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5386866/thomas-j-george-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

184  
papers

2,584  
citations

27  
h-index

43  
g-index

203  
ext. papers

3,560  
ext. citations

4.1  
avg, IF

5.19  
L-index

#	Paper	IF	Citations
184	Impact of preoperative chemoradiotherapy (CRT) on the rectal tumor microenvironment (TME) and associated patient outcomes.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 157-157	2.2	
183	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS233-TPS233 <sup>0</sup>	2.2	0
182	A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS619-TPS619	2.2	
181	NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study <sup>0</sup> randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS232-TPS232	2.2	0
180	Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 140-140	2.2	
179	Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 575-575	2.2	
178	Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102492	2.2	4
177	Landscape of , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in -Mutated Cancers.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100245	3.6	2
176	Administration of Immune Checkpoint Inhibitors Near the End of Life.. <i>JCO Oncology Practice</i> , <b>2022</b> , OP210680	2.1	0
175	Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 105, 102376	14.4	0
174	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 801379	5.3	3
173	Comment on "A National Cancer Database Analysis of Microsatellite Instability and Pathologic Complete Response in Locally Advanced Rectal Cancer". <i>Annals of Surgery</i> , <b>2021</b> , 274, e197-e198	7.8	
172	Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery. <i>Cancer Medicine</i> , <b>2021</b> , 11, 50	4.8	2
171	Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma. <i>Cureus</i> , <b>2021</b> , 13, e19037	1.2	
170	A Statistical Method for Association Analysis of Cell Type Compositions.. <i>Statistics in Biosciences</i> , <b>2021</b> , 13, 373-385	1.5	
169	Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients. <i>Journal of Palliative Care</i> , <b>2021</b> , 36, 211-218	1.8	
168	A Subjective Culture Approach to Cancer Prevention: Rural Black and White Adults' Perceptions of Using Virtual Health Assistants to Promote Colorectal Cancer Screening. <i>Health Communication</i> , <b>2021</b> , 1-12	3.2	0

167	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC) NRG-GI004/SWOG-S1610.. <i>Journal of Clinical</i>	2.2	5
166	ImmunoTherapy Management in Special Cancer Patient Populations. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, 240-245	2.3	4
165	A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4170-TPS4170	2.2	
164	The association between cognitive impairment and breast and colorectal cancer screening utilization. <i>BMC Cancer</i> , <b>2021</b> , 21, 539	4.8	0
163	Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer's disease. <i>Npj Digital Medicine</i> , <b>2021</b> , 4, 84	15.7	2
162	Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , <b>2021</b> , 26, 825-e1674	5.7	3
161	Key changes to improve social presence of a virtual health assistant promoting colorectal cancer screening informed by a technology acceptance model. <i>BMC Medical Informatics and Decision Making</i> , <b>2021</b> , 21, 196	3.6	1
160	A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, 1-19	3.8	3
159	Neratinib-Plus-Cetuximab in Quadruple-WT ( ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1612-1622	12.9	3
158	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 404-411	4	0
157	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 400-407	9.7	12
156	Establishing and Evaluating an ASCO Learning Cohort: a Longitudinal Project Assessing the Learning Needs and Behaviors of Oncology Professionals. <i>Journal of Cancer Education</i> , <b>2021</b> , 36, 478-483 <sup>1.8</sup>		
155	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS148-TPS148 <sup>2</sup>	2.2	4
154	NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC) Pembrolizumab experimental arm (EA) primary results.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8-8	2.2	4
153	Extracting social determinants of health from electronic health records using natural language processing: a systematic review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2021</b> , 28, 2716-2727	8.6	7
152	Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. <i>Oncologist</i> , <b>2021</b> , 26, 362-e724	5.7	0
151	The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
150	Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1225-1230	13.4	14

149	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	3
148	A Pilot Study Examining the Efficacy of Delivering Colorectal Cancer Screening Messages via Virtual Health Assistants. <i>American Journal of Preventive Medicine</i> , <b>2021</b> , 61, 251-255	6.1	5
147	Internet-based tailored virtual human health intervention to promote colorectal cancer screening: design guidelines from two user studies. <i>Journal on Multimodal User Interfaces</i> , <b>2021</b> , 15, 147-162	1.7	3
146	New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review. <i>Cancer Medicine</i> , <b>2021</b> , 10, 439-446	4.8	2
145	Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2102538	2.2	6
144	Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes. <b>2021</b> , 2021, 716-725	0.7	
143	Assessing the practice of data quality evaluation in a national clinical data research network through a systematic scoping review in the era of real-world data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2020</b> , 27, 1999-2010	8.6	9
142	How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 557-565	6.1	10
141	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , <b>2020</b> , 17, 757-770	19.4	82
140	Clinical Trial Generalizability Assessment in the Big Data Era: A Review. <i>Clinical and Translational Science</i> , <b>2020</b> , 13, 675-684	4.9	24
139	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS4121-TPS4121	2.2	2
138	A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Intergroup (COIN) study (NCT02104141). <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS261-TPS261	2.2	2
137	NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS261-TPS261	2.2	1
136	Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer@ Disease Trials <b>2020</b> , 2020, 717-726	0.7	2
135	International Classification of Diseases, Tenth Revision, Clinical Modification social determinants of health codes are poorly used in electronic health records. <i>Medicine (United States)</i> , <b>2020</b> , 99, e23818	1.8	11
134	Engineering magnetic nanoparticles and their integration with microfluidics for cell isolation. <i>Journal of Colloid and Interface Science</i> , <b>2020</b> , 564, 204-215	9.3	14
133	Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2717-2723.e3	6.9	3
132	Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer. <i>Journal of Gastrointestinal Oncology</i> , <b>2020</b> , 11, 790-802	2.8	5

131	Incorporation of lateral microfiltration with immunoaffinity for enhancing the capture efficiency of rare cells. <i>Scientific Reports</i> , <b>2020</b> , 10, 14210	4.9	6
130	Assessing the effect of data integration on predictive ability of cancer survival models. <i>Health Informatics Journal</i> , <b>2020</b> , 26, 8-20	3	3
129	A Pilot Study Determining Comprehension and the Acceptability of a Cancer Research Study Website for Cancer Patients and Caregivers. <i>Journal of Cancer Education</i> , <b>2020</b> , 35, 589-598	1.8	3
128	Differential response to targeted acupuncture by gender in patients with gastrointestinal cancer cachexia: secondary analysis of a randomized controlled trial. <i>Acupuncture in Medicine</i> , <b>2020</b> , 38, 53-60	1.9	
127	Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. <i>Cancer Medicine</i> , <b>2020</b> , 9, 4069-4082	4.8	8
126	Tailoring virtual human-delivered interventions: A digital intervention promoting colorectal cancer screening for Black women. <i>Psycho-Oncology</i> , <b>2020</b> , 29, 2048-2056	3.9	3
125	Rural-urban disparities in tobacco retail access in the southeastern United States: CVS vs. the dollar stores. <i>Preventive Medicine Reports</i> , <b>2019</b> , 15, 100935	2.6	2
124	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. <i>Oncology</i> , <b>2019</b> , 97, 102-111	3.6	38
123	Innenrücktitelbild: Integration of Lateral Filter Arrays with Immunoaffinity for Circulating-Tumor-Cell Isolation (Angew. Chem. 23/2019). <i>Angewandte Chemie</i> , <b>2019</b> , 131, 7961-7961	3.6	
122	Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 1131-1141	9.7	56
121	The Proteome of Pancreatic Cancer-Derived Exosomes Reveals Signatures Rich in Key Signaling Pathways. <i>Proteomics</i> , <b>2019</b> , 19, e1800394	4.8	11
120	Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. <i>Cancer Medicine</i> , <b>2019</b> , 8, 3314-3324	4.8	10
119	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , <b>2019</b> , 125, 2732-2746	6.4	9
118	Integration of Lateral Filter Arrays with Immunoaffinity for Circulating-Tumor-Cell Isolation. <i>Angewandte Chemie</i> , <b>2019</b> , 131, 7688-7692	3.6	2
117	Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1436-1447	2.2	33
116	Predicting unintentional weight loss in patients with gastrointestinal cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2019</b> , 10, 526-535	10.3	12
115	Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma. <i>Theranostics</i> , <b>2019</b> , 9, 1417-1425	12.1	40
114	Integration of Lateral Filter Arrays with Immunoaffinity for Circulating-Tumor-Cell Isolation. <i>Angewandte Chemie - International Edition</i> , <b>2019</b> , 58, 7606-7610	16.4	27

113	Augmentation of Cancer Cachexia Components With Targeted Acupuncture in Patients With Gastrointestinal Cancers: A Randomized Controlled Pilot Study. <i>Integrative Cancer Therapies</i> , <b>2019</b> , 18, 1534735418823269	3	11
112	Thermal ablation versus wedge or segmental resection in patients with early stage hepatocellular carcinoma: a population survival analysis. <i>Hpb</i> , <b>2019</b> , 21, 249-257	3.8	2
111	Using photography to explore psychological distress in patients with pancreatic cancer and their caregivers: a qualitative study. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 321-328	3.9	8
110	Facilitation or Hindrance: Physicians' Perception on Best Practice Alerts (BPA) Usage in an Electronic Health Record System. <i>Health Communication</i> , <b>2019</b> , 34, 942-948	3.2	6
109	The Influence of Patient Identification and Narrative Transportation on Intentions to Participate in Cancer Research. <i>Journal of Cancer Education</i> , <b>2019</b> , 34, 725-734	1.8	8
108	Two Cases of Rare Pancreatic Malignancies. <i>Journal of Pancreatic Cancer</i> , <b>2019</b> , 5, 26-33	1.5	3
107	NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC) First experimental arm (EA) initial results.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3505-3505	2.2	10
106	NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or n plus cetuximab (C) in patients (pts) with "quadruple wild-type (WT)" (KRAS/NRAS/BRAF/PIK3CA WT) metastatic colorectal cancer (mCRC) based on HER2 status Amplified (amp), non-amplified (non-amp), WT, or	2.2	2
105	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC).. <i>Journal of</i>	2.2	3
104	Assessing the Validity of a Patient-Trial Generalizability Score using Real-world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial Case Study <b>2019</b> , 2019, 1101-1110	0.7	4
103	Creating an mHealth App for Colorectal Cancer Screening: User-Centered Design Approach. <i>JMIR Human Factors</i> , <b>2019</b> , 6, e12700	2.5	22
102	A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS721-TPS721	2.2	
101	Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS3620-TPS3620	2.2	
100	5-FU induced cardiotoxicity: case series and review of the literature. <i>Cardio-Oncology</i> , <b>2019</b> , 5, 13	2.8	14
99	Tobacco and E-cigarette use among cancer survivors in the United States. <i>PLoS ONE</i> , <b>2019</b> , 14, e0226110	3.7	22
98	Pancreas Cancer-Associated Weight Loss. <i>Oncologist</i> , <b>2019</b> , 24, 691-701	5.7	56
97	Should Upfront Chemotherapy Precede Preoperative Chemoradiotherapy and Surgery in Locally Advanced Rectal Cancer? <b>2018</b> , 287-297		
96	Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 460-466	9.7	13

95	Design and rationale for the precision medicine guided treatment for cancer pain pragmatic clinical trial. <i>Contemporary Clinical Trials</i> , <b>2018</b> , 68, 7-13	2.3	11
94	Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 1-12	3.8	62
93	Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease. <i>Cancer</i> , <b>2018</b> , 124, 3510-3519	6.4	32
92	Rural-urban and racial-ethnic differences in awareness of direct-to-consumer genetic testing. <i>BMC Public Health</i> , <b>2018</b> , 18, 277	4.1	15
91	An ontology-guided semantic data integration framework to support integrative data analysis of cancer survival. <i>BMC Medical Informatics and Decision Making</i> , <b>2018</b> , 18, 41	3.6	23
90	Objective Preoperative Parameters Predict Difficult Pelvic Dissections and Clinical Outcomes. <i>Journal of Surgical Research</i> , <b>2018</b> , 232, 15-25	2.5	4
89	Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). <i>Cancer</i> , <b>2018</b> , 124, 688-697	6.4	2
88	Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. <i>Journal of Gastrointestinal Cancer</i> , <b>2018</b> , 49, 1-8	1.6	9
87	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , <b>2018</b> , 9, 610-617	2.8	131
86	Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis. <i>Journal of Gastrointestinal Oncology</i> , <b>2018</b> , 9, 536-545	2.8	13
85	Providers' Perceptions of Barriers to Optimal Communication With Patients During the Postcolonoscopy Experience. <i>Journal of Patient Experience</i> , <b>2018</b> , 5, 272-278	1.3	1
84	A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 2399-2407	4.4	7
83	Extragastrintestinal stromal tumors of the pelvic cavity and the vagina: Two case reports and review of the literature. <i>Gynecologic Oncology Reports</i> , <b>2018</b> , 25, 3-7	1.3	12
82	Body composition changes differ by gender in stomach, colorectal, and biliary cancer patients with cachexia: Results from a pilot study. <i>Cancer Medicine</i> , <b>2018</b> , 7, 3695-3703	4.8	15
81	Tumor cell isolation in microfluidic devices for cancer treatment monitoring <b>2017</b> ,		1
80	Influential factors on treatment decision making among patients with colorectal cancer: A scoping review. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 2943-2951	3.9	10
79	Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease. <i>Pancreas</i> , <b>2017</b> , 46, 813-819	2.6	28
78	Sociodemographic factors associated with stage of diagnosis and treatment uptake among patients with colorectal cancer: A brief report. <i>Journal of Cancer Policy</i> , <b>2017</b> , 12, 79-82	1	1

77	Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy. <i>Oncology Letters</i> , <b>2017</b> , 13, 1087-1094	2.6	9
76	A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. <i>Surgery</i> , <b>2017</b> , 161, 930-938	3.6	28
75	Innovation or Inconsistency? Framing Colorectal Cancer Guidelines to Improve Public Perceptions of Updated Screening Recommendations. <i>Journal of Language and Social Psychology</i> , <b>2017</b> , 36, 14-27	1.2	2
74	Infusion Room-Based Transition to Practice Model for Teaching Cancer Systemic Therapy Management. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, e909-e915	3.1	
73	Management of Malignant Bowel Obstruction Associated With GI Cancers. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, 426-434	3.1	30
72	Neoadjuvant transarterial radiation lobectomy for colorectal hepatic metastases: a small cohort analysis on safety, efficacy, and radiopathologic correlation. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, E43-E51	2.8	16
71	A Novel Microfluidic Device for Isolation of Circulating Tumor Cells from Pancreatic Cancer Blood Samples. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1634, 33-53	1.4	6
70	Randomized Clinical Trials in Colon and Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , <b>2017</b> , 26, 689-704	2.7	20
69	Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 861-867	3.5	35
68	The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. <i>Current Treatment Options in Oncology</i> , <b>2017</b> , 18, 73	5.4	4
67	Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. <i>Cancer Research</i> , <b>2017</b> , 77, 672-683	10.1	18
66	Data Integration through Ontology-Based Data Access to Support Integrative Data Analysis: A Case Study of Cancer Survival <b>2017</b> , 2017, 1300-1303	0.8	7
65	NRG-GI002: A phase II clinical trial platform for total neoadjuvant therapy (TNT) in rectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS3629-TPS3629	2.2	4
64	Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS814-TPS814	2.2	2
63	Cancer Survivorship History and Physical. <i>Southern Medical Journal</i> , <b>2017</b> , 110, 37-44	0.6	2
62	Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia. <i>Oncotarget</i> , <b>2017</b> , 8, 1177-1189	3.3	18
61	NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. <i>Oncotarget</i> , <b>2017</b> , 8, 57246-57264	3.3	8
60	Analysis of the Cost Effectiveness of Laparoscopic Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , <b>2017</b> , 21, 1404-1410	3.3	17



59	Explore Care Pathways of Colorectal Cancer Patients with Social Network Analysis. <i>Studies in Health Technology and Informatics</i> , <b>2017</b> , 245, 1270	0.5	1
58	Use of Electronic Cigarettes Among Cancer Survivors in the U.S. <i>American Journal of Preventive Medicine</i> , <b>2016</b> , 51, 762-766	6.1	16
57	Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 186-93	2.2	3
56	"It is just another test they want to do": Patient and caregiver understanding of the colonoscopy procedure. <i>Patient Education and Counseling</i> , <b>2016</b> , 99, 651-658	3.1	14
55	Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1787-99	12.9	22
54	Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3533-3533	2.2	6
53	A phase II clinical trial platform utilizing total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS3638-TPS3638	2.2	2
52	Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, 173-80	2.8	3
51	EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, 838-847	2.8	3
50	Clinical, morphologic, and immunophenotypic characteristics of ampullary carcinomas with an emphasis on SMAD4 expression. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, 974-981	2.8	1
49	Assessing the population representativeness of colorectal cancer treatment clinical trials. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , <b>2016</b> , 2016, 2970-2973	0.9	3
48	Standardization of surgical care in a high-volume center improves survival in resected pancreatic head cancer. <i>American Journal of Surgery</i> , <b>2016</b> , 212, 195-201.e1	2.7	16
47	Oncologic and Perioperative Outcomes Following Selective Application of Laparoscopic Pancreaticoduodenectomy for Periapillary Malignancies. <i>Journal of Gastrointestinal Surgery</i> , <b>2016</b> , 20, 1343-9	3.3	53
46	Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1336-41	10.3	57
45	Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. <i>American Journal of Pathology</i> , <b>2016</b> , 186, 1537-46	5.8	23
44	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 1306-1314	5.7	27
43	Interobserver variability of mitotic index and utility of PHH3 for risk stratification in gastrointestinal stromal tumors. <i>American Journal of Clinical Pathology</i> , <b>2015</b> , 143, 385-92	1.9	21
42	Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 1553-63	7.4	19

41	Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 80-9	6.1	14
40	Pathways to colonoscopy in the South: seeds of health disparities. <i>American Journal of Public Health</i> , <b>2015</b> , 105, e103-11	5.1	5
39	The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. <i>BMC Cancer</i> , <b>2015</b> , 15, 783	4.8	33
38	Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. <i>Oncoscience</i> , <b>2015</b> , 2, 581-4	0.8	6
37	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 3561-4	4.4	6
36	Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. <i>Current Colorectal Cancer Reports</i> , <b>2015</b> , 11, 275-280	1	81
35	Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. <i>Cancer Medicine</i> , <b>2015</b> , 4, 1224-39	4.8	12
34	Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. <i>Lab on A Chip</i> , <b>2014</b> , 14, 89-98	7.2	194
33	Fellowship engagement in hematology/oncology professionalism training. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1164-6	2.2	
32	Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 682-90	4.3	8
31	"Tissue is the issue": circulating tumor cells in pancreatic cancer. <i>Journal of Gastrointestinal Cancer</i> , <b>2014</b> , 45 Suppl 1, 222-5	1.6	6
30	Src inhibition is still a relevant target in pancreatic cancer. <i>Oncologist</i> , <b>2014</b> , 19, 211	5.7	7
29	Neoadjuvant rectal cancer (RC) score to predict survival: Potential surrogate endpoint for early phase trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3533-3533	2.2	12
28	Argininosuccinate synthase as a novel biomarker for inflammatory conditions. <i>Biomarkers</i> , <b>2013</b> , 18, 242-26	2.6	4
27	Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. <i>Oncology Reports</i> , <b>2013</b> , 29, 1259-67	3.5	85
26	Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 686-93	9.7	40
25	Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. <i>Acta Oncologica</i> , <b>2013</b> , 52, 498-505	3.2	56
24	Characteristics and outcomes of adenosquamous carcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 311-311	2.2	8

23	Characteristics and outcomes of adenosquamous carcinoma of the pancreas. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2013</b> , 6, 75-9		17
22	Squamous cell carcinoma of the anal margin: the university of Florida experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2011</b> , 34, 406-10	2.7	18
21	The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 205-13	6.1	81
20	Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 4-5	9.7	
19	Protocol information provides opportunity for patient safety and quality improvement. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e563	2.2	5
18	Adjuvant high-dose interferon-(alpha) for resected melanoma in a patient with HIV infection. <i>Oncologist</i> , <b>2010</b> , 15, 695-8	5.7	0
17	Hepatitis B reactivation and rituximab in the oncology practice. <i>Oncologist</i> , <b>2010</b> , 15, 1113-21	5.7	20
16	Gastroduodenal ulcerations as a delayed complication of hepatic metastasis radioembolization. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e735-6	2.2	7
15	Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 702-5	9.7	60
14	Definitive radiotherapy for squamous cell carcinoma of the anal canal. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2010</b> , 33, 47-51	2.7	8
13	A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2010</b> , 33, 251-6	2.7	14
12	Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. <i>The Journal of Supportive Oncology</i> , <b>2010</b> , 8, 72-7		29
11	Welcome to the team: trastuzumab in HER2-positive esophagogastric cancers. <i>Community Oncology</i> , <b>2009</b> , 6, 544-545		
10	Radiotherapy in the treatment of resectable rectal adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2009</b> , 32, 629-38	2.7	7
9	Pancreatic heterotopia masquerading as duodenal carcinoid. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2009</b> , 3, 118-20		1
8	Impact of An Annual Hematology/Oncology Fellow Wet Laboratory Program On Fund of Biomedical Knowledge.. <i>Blood</i> , <b>2009</b> , 114, 246-246	2.2	
7	Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes. <i>The Journal of Supportive Oncology</i> , <b>2009</b> , 7, 9-10		5
6	KRAS mutational analysis: ready for prime time?. <i>Community Oncology</i> , <b>2008</b> , 5, 435-436		4

5	Adjuvant radiotherapy for cutaneous melanoma. <i>Cancer</i> , <b>2008</b> , 112, 1189-96	6.4	25
4	Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. <i>Oncologist</i> , <b>2007</b> , 12, 1332-5	5.7	53
3	Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. <i>Current Gastroenterology Reports</i> , <b>2006</b> , 8, 111-20	5	4
2	Factors associated with parameters of engraftment potential of umbilical cord blood. <i>Transfusion</i> , <b>2006</b> , 46, 1803-12	2.9	45
1	Telehealth and Racial Disparities in Colorectal Cancer Screening: A Pilot Study of How Virtual Clinician Characteristics Influence Screening Intentions. <i>Journal of Clinical and Translational Science</i> , 1-29 <sup>0.4</sup>		0